Real-world long-term outcomes of non-small cell lung cancer patients undergoing neoadjuvant treatment with or without immune checkpoint inhibitors
NAIT exhibited superior efficacy to NACT for NSCLC, resulting in longer OS and EFS. The OS and EFS benefits were also observed among patients in the NAIT group who did not achieve pCR.
Authors
- Bolun Zhou (ORCID: https://orcid.org/0000-0001-8143-4852)
- Qilin Huai
- Fengwei Tan
- Liang Zhao (ORCID: https://orcid.org/0000-0001-9244-3121)
- Wei Guo (ORCID: https://orcid.org/0000-0001-8302-8292)
- Shugeng Gao (ORCID: https://orcid.org/0000-0003-3171-5319)
- Fan Zhang (ORCID: https://orcid.org/0009-0002-8365-3340)
- Lin Li (ORCID: https://orcid.org/0000-0002-3597-3350)
- Qi Xue (ORCID: https://orcid.org/0000-0002-5086-4654)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Shandong Provincial Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Chinese Medical Journal
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1097/cm9.0000000000003551
- Citations
- 2
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04